<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528006</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <secondary_id>otostl-0319</secondary_id>
    <nct_id>NCT02528006</nct_id>
  </id_info>
  <brief_title>Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges</brief_title>
  <official_title>Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kumamoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hokkaido University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yokohama City University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kumamoto University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For adductor spasmodic dysphonia, there is a need for establishing a new therapy under the
      present circumstance where no standard therapy has been established yet and existing
      therapies fail to provide permanent effect. Evaluation of the efficacy of type 2 thyroplasty
      using titanium bridges will expand the therapeutic options available for adductor spasmodic
      dysphonia and establishment of a standard therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spasmodic dysphonia is a type of functional dysphonia not associated with any organic
      abnormality or palsy of the larynx. The speech disorder in this disease is caused by
      involuntary and intermittent spasms of the intralaryngeal muscles (Castelon, 2002).

      There is no curative treatment for this disease. Conservative therapies include voice
      training (voice therapy) and muscle relaxant medication to ease the tension in the larynx
      during speech, although there is not much evidence to support the effectiveness of either. An
      internationally employed therapy is local injection of botulinum toxin A into the
      intralaryngeal muscles to suppress involuntary movements of the vocal cords. The injection
      can be administered percutaneously from the anterior neck within a short time, and a number
      of reports have indicated a greater than 90% efficacy of this treatment (Tisch 2003, Blitzer
      2010). However, this local injection therapy is effective only for a limited period of 3 to 4
      months, and periodic injections have to be continued throughout life for maintaining relief
      from the symptoms under the present circumstances.

      Type 2 thyroplasty is an operative procedure in which the thyroid cartilage is incised at the
      midline, and the incised gap is opened and fixed with the thyroarytenoid muscles attached on
      both sides, so that the vocal cords do not shut too tightly during speech even with strong
      adduction of the glottis, as the symptoms of adductor spasmodic dysphonia are caused by
      excessive closure of the glottis due to strong involuntary and intermittent adduction of the
      intralaryngeal muscles (Isshiki 2001).

      In 2002, the titanium bridge made of biocompatible pure titanium was developed in Japan for
      exclusive use in type 2 thyroplasty (Isshiki 2004). When the titanium bridge was used in
      actual cases, the symptoms disappeared without recurrence after the operation (Sanuki 2007,
      Sanuki 2009, Isshiki &amp; Sanuki 2009, Sanuki 2010).

      There is a need for establishing a new therapy under the present circumstance where no
      standard therapy has been established yet and existing therapies fail to provide permanent
      effect. Evaluation of the efficacy of type 2 thyroplasty using titanium bridges will expand
      the therapeutic options available for adductor spasmodic dysphonia and establishment of a
      standard therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2015</start_date>
  <completion_date type="Actual">March 29, 2017</completion_date>
  <primary_completion_date type="Actual">March 29, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VHI-10 scores assessed by Change from baseline in VHI-10 scores at 13 weeks after surgery</measure>
    <time_frame>13 weeks after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in VHI,VHI-10 scores assessed by Changes in VHI-10 scores before and after surgery</measure>
    <time_frame>52 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in VHI,VHI-10 scores assessed by Changes in VHI scores before and after surgery</measure>
    <time_frame>52 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in VHI,VHI-10 scores assessed by Changes in VHI subscale scores in the functional (F), (P), and (E)</measure>
    <time_frame>52 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in VHI,VHI-10 scores assessed by Changes in phonatory function test results before and after surgery</measure>
    <time_frame>52 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in VHI,VHI-10 scores assessed by Changes in acoustic analysis results</measure>
    <time_frame>52 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in VHI,VHI-10 scores assessed by Frequency of adverse events and device defects</measure>
    <time_frame>52 weeks after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Adductor Spasmodic Dysphonia</condition>
  <arm_group>
    <arm_group_label>Titanium Bridges</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Type 2 Thyroplasty using Titanium Bridges</intervention_name>
    <arm_group_label>Titanium Bridges</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of adductor spasmodic dysphonia by a board certified otorhinolaryngologist
             certified by the Oto-Rhino-Laryngological Society of Japan, Inc.

          2. At least 1 year experience of subjective or objective labored speech production, or
             pauses on certain sounds, due to adductor spasmodic dysphonia

          3. A total score of 20 or more on the Voice Handicap Index-10 (VHI-10)

          4. Non-responders to voice therapy performed before informed consent

          5. 18 through 80 years of age inclusive at the time of informed consent

          6. Written informed consent to participate in this study, provided by patients or their
             legally acceptable representatives

        Exclusion Criteria:

          1. Dysphagia, laryngeal paralysis, or any structural disorder in the vocal cord

          2. Previous surgery for adductor spasmodic dysphonia

          3. Local injection of botulinum toxin type A into the intralaryngeal muscles within 6
             months before informed consent

          4. Serious concomitant diseases

          5. Surgery with general anesthesia scheduled during the study period or surgery performed
             within the past 4 weeks

          6. Participation in any other study using any other intervention within 12 weeks before
             informed consent, or planned participation in such a study during the study period
             after enrollment in this study

          7. Psychiatric disorder requiring treatment, or mental or intellectual disability that
             may affect the conduct of the study

          8. A history of alcoholism or drug abuse

          9. A history of hypersensitivity to pure titanium

         10. Women who are pregnant or planning to become pregnant during the study period

         11. Patients deemed ineligible for this study by the investigator for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetsuji Sanuki, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Otolaryngology,Kumamoto University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8638</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Castelon Konkiewitz E, Trender-Gerhard I, Kamm C, Warner T, Ben-Shlomo Y, Gasser T, Conrad B, Ceballos-Baumann AO. Service-based survey of dystonia in munich. Neuroepidemiology. 2002 Jul-Aug;21(4):202-6.</citation>
    <PMID>12065883</PMID>
  </reference>
  <reference>
    <citation>Ryuichi Yamazaki. Epidemiological Investigation on Spasmodic Dysphonia: Investigation by Questionnaire. The Japan Journal of Logopedics and Phoniatrics. 2001;42(4):343-347</citation>
  </reference>
  <reference>
    <citation>Sulica L. Contemporary management of spasmodic dysphonia. Curr Opin Otolaryngol Head Neck Surg. 2004 Dec;12(6):543-8. Review.</citation>
    <PMID>15548915</PMID>
  </reference>
  <reference>
    <citation>Ludlow CL, Adler CH, Berke GS, Bielamowicz SA, Blitzer A, Bressman SB, Hallett M, Jinnah HA, Juergens U, Martin SB, Perlmutter JS, Sapienza C, Singleton A, Tanner CM, Woodson GE. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg. 2008 Oct;139(4):495-505. doi: 10.1016/j.otohns.2008.05.624. Review.</citation>
    <PMID>18922334</PMID>
  </reference>
  <reference>
    <citation>Tisch SH, Brake HM, Law M, Cole IE, Darveniza P. Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients-an Australian experience. J Clin Neurosci. 2003 Jul;10(4):434-8.</citation>
    <PMID>12852881</PMID>
  </reference>
  <reference>
    <citation>Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. Eur J Neurol. 2010 Jul;17 Suppl 1:28-30. doi: 10.1111/j.1468-1331.2010.03047.x.</citation>
    <PMID>20590805</PMID>
  </reference>
  <reference>
    <citation>Schwartz SR, Cohen SM, Dailey SH, Rosenfeld RM, Deutsch ES, Gillespie MB, Granieri E, Hapner ER, Kimball CE, Krouse HJ, McMurray JS, Medina S, O'Brien K, Ouellette DR, Messinger-Rapport BJ, Stachler RJ, Strode S, Thompson DM, Stemple JC, Willging JP, Cowley T, McCoy S, Bernad PG, Patel MM. Clinical practice guideline: hoarseness (dysphonia). Otolaryngol Head Neck Surg. 2009 Sep;141(3 Suppl 2):S1-S31. doi: 10.1016/j.otohns.2009.06.744.</citation>
    <PMID>19729111</PMID>
  </reference>
  <reference>
    <citation>Tsuji DH, Chrispim FS, Imamura R, Sennes LU, Hachiya A. Impact in vocal quality in partial myectomy and neurectomy endoscopic of thyroarytenoid muscle in patients with adductor spasmodic dysphonia. Braz J Otorhinolaryngol. 2006 Mar-Apr;72(2):261-6.</citation>
    <PMID>16951863</PMID>
  </reference>
  <reference>
    <citation>Nakamura K, Muta H, Watanabe Y, Mochizuki R, Yoshida T, Suzuki M. Surgical treatment for adductor spasmodic dysphonia--efficacy of bilateral thyroarytenoid myectomy under microlaryngoscopy. Acta Otolaryngol. 2008;128(12):1348-53. doi: 10.1080/00016480801965019.</citation>
    <PMID>18607929</PMID>
  </reference>
  <reference>
    <citation>Isshiki N, Haji T, Yamamoto Y, Mahieu HF. Thyroplasty for adductor spasmodic dysphonia: further experiences. Laryngoscope. 2001 Apr;111(4 Pt 1):615-21.</citation>
    <PMID>11359129</PMID>
  </reference>
  <reference>
    <citation>Isshiki N, Yamamoto I, Fukagai S. Type 2 thyroplasty for spasmodic dysphonia: fixation using a titanium bridge. Acta Otolaryngol. 2004 Apr;124(3):309-12.</citation>
    <PMID>15141760</PMID>
  </reference>
  <reference>
    <citation>Sanuki T, Isshiki N. Overall evaluation of effectiveness of type II thyroplasty for adductor spasmodic dysphonia. Laryngoscope. 2007 Dec;117(12):2255-9.</citation>
    <PMID>17921901</PMID>
  </reference>
  <reference>
    <citation>Sanuki T, Isshiki N. Outcomes of type II thyroplasty for adductor spasmodic dysphonia: analysis of revision and unsatisfactory cases. Acta Otolaryngol. 2009 Nov;129(11):1287-93. doi: 10.3109/00016480802620639.</citation>
    <PMID>19863326</PMID>
  </reference>
  <reference>
    <citation>Isshiki N, Sanuki T. Surgical tips for type II thyroplasty for adductor spasmodic dysphonia: modified technique after reviewing unsatisfactory cases. Acta Otolaryngol. 2010 Feb;130(2):275-80. doi: 10.3109/00016480903036255.</citation>
    <PMID>19513892</PMID>
  </reference>
  <reference>
    <citation>Sanuki T, Yumoto E, Minoda R, Kodama N. Effects of type II thyroplasty on adductor spasmodic dysphonia. Otolaryngol Head Neck Surg. 2010 Apr;142(4):540-6. doi: 10.1016/j.otohns.2009.12.018.</citation>
    <PMID>20304275</PMID>
  </reference>
  <reference>
    <citation>Tetsuji Sanuki, Eiji Yumoto, Narihiro Kodama. Management of Adductor Spasmodic Dysphonia. The Larynx Japan. 2012;24(2):80-83</citation>
  </reference>
  <reference>
    <citation>Chan SW, Baxter M, Oates J, Yorston A. Long-term results of type II thyroplasty for adductor spasmodic dysphonia. Laryngoscope. 2004 Sep;114(9):1604-8.</citation>
    <PMID>15475790</PMID>
  </reference>
  <reference>
    <citation>Jacobson BH, Johnson A, Grywalski C, et al: The Voice Handicap Index (VHI): development and validation. Am J Speech-Lang Pathol, 1997; 6: 66-70.</citation>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spasmodic Dysphonia</keyword>
  <keyword>Type 2 Thyroplasty</keyword>
  <keyword>Titanium Bridges</keyword>
  <keyword>Operation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysphonia</mesh_term>
    <mesh_term>Hoarseness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

